Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Whittier, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Whittier, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Clearwater, FL
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Hialeah, FL
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Hialeah, FL
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Tampa, FL
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Peachtree City, GA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Peachtree City, GA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cedar Rapids, IA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Jackson, MS
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Jackson, MS
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Kalispell, MT
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Kalispell, MT
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New York, NY
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New York, NY
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Charlotte, NC
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cincinnati, OH
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Columbus, OH
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Duncansville, PA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wyomissing, PA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wyomissing, PA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Charleston, SC
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Orangeburg, SC
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Rock Hill, SC
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Hixson, TN
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Hixson, TN
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Memphis, TN
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
McKinney, TX
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
McKinney, TX
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Webster, TX
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Webster, TX
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Arlington, VA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Arlington, VA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Spokane, WA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Beckley, WV
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Beckley, WV
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Clarksburg, WV
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Clarksburg, WV
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Capital Federal,
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Capital Federal,
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Leandro, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Leandro, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Saint Clair Shores, MI
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Saint Clair Shores, MI
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Las Vegas, NV
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
West Bloomfield, MI
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
West Bloomfield, MI
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Paradise Valley, AZ
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cypress, TX
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cypress, TX
Click here to add this to my saved trials
Intervention to Improve Quality of Life in African American Lupus Patients
Intervention to Improve Quality of Life for African-AmericaN Lupus Patients (IQAN)
Status: Enrolling
Updated:  12/31/1969
Institute for Partnerships to Eliminate Health Disparities, University of South Carolina
mi
from
Columbia, SC
Intervention to Improve Quality of Life in African American Lupus Patients
Intervention to Improve Quality of Life for African-AmericaN Lupus Patients (IQAN)
Status: Enrolling
Updated: 12/31/1969
Institute for Partnerships to Eliminate Health Disparities, University of South Carolina
mi
from
Columbia, SC
Click here to add this to my saved trials
ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Wexner Medical Center, Nephrology Clinical Trials Unit
mi
from
Columbus, OH
ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Wexner Medical Center, Nephrology Clinical Trials Unit
mi
from
Columbus, OH
Click here to add this to my saved trials
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
UCSD
mi
from
San Diego, CA
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
UCSD
mi
from
San Diego, CA
Click here to add this to my saved trials
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
UCSF School of Medicine
mi
from
San Francisco, CA
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
UCSF School of Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
University of Miami Hospitals and Clinics
mi
from
Miami, FL
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
University of Miami Hospitals and Clinics
mi
from
Miami, FL
Click here to add this to my saved trials
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Click here to add this to my saved trials